Spots Global Cancer Trial Database for SarCNU in Treating Patients With Recurrent Malignant Glioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: SarCNU in Treating Patients With Recurrent Malignant Glioma

Official Title: A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma

Study ID: NCT00036660

Conditions

Brain and Central Nervous System Tumors

Interventions

SarCNU

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent malignant glioma.

Detailed Description: OBJECTIVES: * Determine the efficacy of SarCNU, in terms of objective response and duration of response, in patients with recurrent malignant gliomas. * Determine the qualitative and quantitative toxic effects of this drug in these patients. * Determine the time to progression and survival of patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive oral SarCNU on days 1, 5, and 9. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.